- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02580266
Blood/Urine Markers for Drug Discovery for Renal Disease in Diabetes (DDRD)
Diabetic nephropathy (kidney problems caused by diabetes) is a devastating chronic vascular complication of diabetes. New treatments are urgently needed for preventing or slowing down the progression of diabetic kidney disease. Samples of serum/plasma/urine will be obtained from patients with diabetes and different degree of renal impairment.
In this project cells in culture will be treated with plasma or serum or urine; cells extracts or supernatant will be studied to screen for modulation (activation/inhibition) of different cellular pathways using gene array, metabolomic and/or proteomic. Once some cellular pathways have been identified specific analysis will be conducted on the biological material collected to confirm specific "cell signatures" that could represent potential target for treatment.
Study Overview
Status
Conditions
Detailed Description
The aim of the study is to investigate novel putative mechanisms involved in the pathophysiology of kidney disease in diabetic patients.
The investigators will make use of plasma, serum or urine obtained from patients with diabetes.
Cells in culture will be treated with plasma or serum or urine; cells extracts or supernatant will be studied to screen for modulation (activation/inhibition) of different cellular pathways using gene array, metabolomic and/or proteomic. Once some cellular pathways have been identified specific analysis will be conducted on the biological material collected to confirm specific "cell signatures" that could represent potential target for treatment.
The investigators will recruit patients with both type 1 and type 2 diabetes attending our outpatient diabetes clinic at Guys' and St Thomas Hospital. The participant will be informed of the aim of the research and if agreeable in donating blood and urine sample; participants will be asked to sign a written informed consent explaining in simple word the aim of the research, the involvement they should have (blood sample and urine sample collection), the minimal risk to which they will be exposed (venopuncture).
The study will involve one or more blood collections from the arm, for up to 30 mls (6 tea spoons) per year (up to 10 yeas duration), to be collected on up to 2 occasions/ year (minimum time between two collections: 4 weeks), with up to 15ml (3 tea spoon) of blood maximum volume taken per occasion. Urine samples (any amount) might also be collected at any time. Blood and urine collections will take approximately 15 minutes.
This research is low risk. Samples will be stored within the Unit of Metabolic Medicine (Dr Gnudi), King's College London, United Kingdom, and its potential future use will be within the remit of the advancement of science and for the benefit of public domain within academic and/or commercial organisations (e.g. pharmaceutical industry) worldwide.
Any information collected from participants during the course of the research will be kept strictly confidential. Any information leaving the hospital will have the name and address of patient removed so that it can not be recognised by third parties.
The results obtained from this research will likely to be published in a medical journal. The investigators will provide copy of any published results to anybody that may request for it. Participants will not be identified in any report/publication.
Study Type
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SE1 9RT
- Unit for Metabolic Medicine, King's College London
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- type 1 and type 2 diabetes
Exclusion Criteria:
- major acute cardio (myocardial infarct, stroke, ec) renal (acute renal failure) events, or severe debilitating disease (e.g. cancer) during the 6 months before the blood/urine collection.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cellular phenotype
Time Frame: 5 years
|
Cellular phenotype (gene and protein expression level)
|
5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Luigi Gnudi, MD, PhD, King's College London
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Version-2, 01 Sept 2015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Complications
-
Hennepin Healthcare Research InstituteCompletedHyperglycemia | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Complications of Diabetes Mellitus | Diabetes-Related ComplicationsUnited States
-
Royal Prince Alfred Hospital, Sydney, AustraliaMerck Sharp & Dohme LLCCompletedDiabetes Related Complications
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Seoul St. Mary's HospitalUnknownComplications of Diabetes MellitusKorea, Republic of
-
University of AvignonCompletedDiabetes-related ComplicationsFrance
-
Albert Einstein College of MedicineJuvenile Diabetes Research Foundation; National Institutes of Health (NIH)Completed
-
Naestved HospitalUnknown
-
University of Campinas, BrazilConselho Nacional de Desenvolvimento Científico e Tecnológico; ANS PharmaUnknownDiabetes Mellitus, Type 2 | Insulin Resistance | Diabetes-Related ComplicationsBrazil
-
University of AarhusUnknownDiabetes Mellitus, Type 2 | Diabetic Neuropathies | Autonomic Neuropathy | Diabetic Complications Neurological | Polyneuropathy DiabetesDenmark
-
Rambam Health Care CampusUnknown